Alison R. Walker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alison R. Walker has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Kuykendall
Moffitt Cancer Center, Tampa, FL
26 shared publications - Caroline Fileni
Hematology department Nice University Hospital Nice France
26 shared publications - Chia-Ho Cheng
H. Lee Moffitt Cancer Center and Research Institute 4 Department of Biostatistics and Bioinformatics Tampa, Florida
26 shared publications - Dahui Qin
H. Lee Moffitt Cancer Center and Research Institute 5 Department of Pathology Tampa, Florida
26 shared publications - David A. Sallman
Department of Malignant Hematology H. Lee Moffitt Cancer Center Tampa Florida USA
26 shared publications - Dimitrios Drekolias
H. Lee Moffitt Cancer Center 1 Malignant Hematology Department Tampa, Florida
26 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Table 7. Targeted Next Generation Sequencing (NGS) panels used for the Moffitt Cancer Center, Nice University Hospital, and University of Maryland Cohorts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Table 7. Targeted Next Generation Sequencing (NGS) panels used for the Moffitt Cancer Center, Nice University Hospital, and University of Maryland Cohorts.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Table 2. Predictors of complete response with (CR) or without (CRi) count recovery.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Table 2. Predictors of complete response with (CR) or without (CRi) count recovery.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 10. Nested Bootstrap Analysis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 10. Nested Bootstrap Analysis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 1. Study Flow and Model Development Pipeline.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 1. Study Flow and Model Development Pipeline.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 12. Comparison of Risk Group Classifications Between the Moffitt Model vs. Other Prognostic Models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 12. Comparison of Risk Group Classifications Between the Moffitt Model vs. Other Prognostic Models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Table 3. Predictors of Overall Survival.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Table 3. Predictors of Overall Survival.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 6. OS outcomes based on clinical factors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 6. OS outcomes based on clinical factors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 15 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 15. Effect of Genetic Risk, AML Subtype, Prior HMA Exposure, and Allo-SCT on OS.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 15 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 15. Effect of Genetic Risk, AML Subtype, Prior HMA Exposure, and Allo-SCT on OS.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 8. Impact of TP53 Mutation and Complex Karyotype on Multivariable Coefficients and Collinearity.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 8. Impact of TP53 Mutation and Complex Karyotype on Multivariable Coefficients and Collinearity.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 5. Frequency of genetic alterations in the Moffitt AML cohort.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Supplementary Figure 5. Frequency of genetic alterations in the Moffitt AML cohort.